Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 6 Ovarian Neoplasms 4 Endometrial Neoplasms 3 Pancreatic Neoplasms 2 Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Bulbo-Spinal Atrophy, X-Linked 1 Biliary Tract Neoplasms 1 Advanced Breast Cancer 1 Adenocarcinoma of Lung 1

Interventions

Letrozole 5 Fulvestrant 5 trastuzumab deruxtecan 3 Injections 3 toripalimab 2 sacituzumab govitecan 2 palbociclib 2 elacestrant 2 abemaciclib 2 Anastrozole 2 AZD9833 2 ribociclib 1 pyrotinib 1 exemestane 1 eribulin 1 disitamab vedotin 1 dalpiciclib 1 Vinorelbine 1 Selective Estrogen Receptor Modulators 1 Ritonavir 1 RAD1901 1 Paclitaxel 1 Lead 1 Itraconazole 1 Goserelin 1 Gonadotropin-Releasing Hormone 1 Everolimus 1 Docetaxel 1 Bevacizumab 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × AZD5305 × 1 year × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡